NCT05427435 (Innov Marshall) is a NA clinical trial of Marshall ethanolisation in Atrial Fibrillation, sponsored by University Hospital, Bordeaux.

Who is sponsoring NCT05427435?

NCT05427435 is sponsored by University Hospital, Bordeaux.

What drugs are being tested in NCT05427435?

Interventions in NCT05427435: Marshall ethanolisation.

What condition does NCT05427435 study?

NCT05427435 studies Atrial Fibrillation.

Is NCT05427435 still recruiting?

NCT05427435 is currently recruiting now. Last updated 17 June 2025.

Last reviewed 2025-06-17 · How we verify

NCT05427435: Innov Marshall

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Feasibility of Ethanolization of Vein of Marshall With Specific Catheter in Atrial Fibrillation Ablation

Recruiting now NA Last updated 17 June 2025

What this trial tests

NA trial testing Marshall ethanolisation in Atrial Fibrillation in 40 participants. Currently enrolling.

Timeline

9 May 2022

Primary endpoint
16 May 2027

30 May 2027

Quick facts

Lead sponsor	University Hospital, Bordeaux
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	40
Start date	9 May 2022
Primary completion	16 May 2027
Estimated completion	30 May 2027
Sites	1 location across France

Drugs / interventions tested

Marshall ethanolisation

Conditions studied

Atrial Fibrillation — all drugs for Atrial Fibrillation →

Sponsor

University Hospital, Bordeaux

Who can join

18 and older, any sex, with Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In patients with persistent AF (PsAF), ablation limited to pulmonary vein (PV) isolation is the most straightforward approach, but results only in 50% of arrhythmia freedom at 1 year follow-up. Substrate modification strategies have failed to demonstrate their superiority with variable reported success rate. The Marshall network is a highly arrhythmogenic structure that has not been systematically targeted so far, probably because of the absence of dedicated tools to make its ablation simple and easy. We sought to investigate the use of a specific catheter for visualization and ethanolization of vein of Marshall allowing to systematically include this target in the ablation set. The main objective of this study is to demonstrate the feasibility to use the Targeted Endovascular Delivery (TED) catheter specifically for visualization and ethanolization of vein of Marshall.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

NCT07429214 — A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF · NA · recruiting
NCT07271238 — Feasibility Study on the VERAFEYE Imaging and Navigation System for Guided Catheter Ablation Procedures · NA · recruiting
NCT07388108 — Atrial Dyssynchrony to Predict Arrhythmias in the Postoperative Setting of Cardiovascular Surgery. · recruiting
NCT07428967 — AV Node Ablation and CONDUCTion System Pacing for Atrial Fibrillation With Preserved Left Ventricular Function · NA · recruiting
NCT06650995 — AlEX-DHF: Ablation and Exercise in Diastolic Heart Failure · NA · recruiting

Other University Hospital, Bordeaux trials

Trials by the same sponsor.

NCT07506928 — NEURO - Prognostication Using Late Somatosensory Evoked - Potentials · NA · not yet recruiting
NCT07524036 — Impact of a Nursing Educational Consultation on the Patient's Adherence to Their Post-stroke Care Plan. · NA · not yet recruiting
NCT07527494 — Digital MEDIcal TWIN for the Prediction of Arrhythmic Sudden Cardiac Death After a Myocardial Infarction · NA · not yet recruiting
NCT07527442 — Efficacy and Safety of Circumcision Alone on Risk of Febrile Urinary Tract Infections in Boys With Posterior Urethral Va · Phase 2 · not yet recruiting
NCT07478523 — FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05427435 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Bordeaux
Last refreshed: 17 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05427435.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing